Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03957733
Recruitment Status : Recruiting
First Posted : May 21, 2019
Last Update Posted : May 21, 2019
Sponsor:
Collaborators:
King Faisal Specialist Hospital & Research Center
King Saud Medical City
Al Hada Military Hospital
Information provided by (Responsible Party):
King Abdullah Medical City

Brief Summary:

This is a Phase II/III randomized study involving non-metastatic rectal cancer patients who are candidates for neoadjuvant chemoradiotherapy. Eligible patients will be randomized between two treatment arms:

Experimental arm: Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX and then surgery. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (4 cycles of modified FOLFOX6 or 3 cycles of XELOX).

Standard arm: Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).

The study aims to assess the efficacy of consolidation chemotherapy given in the interval between the end of CRT and surgery to allow for early initiation of systemic therapy aiming to decrease distant relapse rate and enhancing pathological response.


Condition or disease Intervention/treatment Phase
Rectal Cancer Drug: Chemotherapy Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 338 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase II/III randomized controlled parallel group study. Patients are randomized between Chemoradiotherapy followed by surgery or chemoradiotherapy followed by folfox/xelox chemotherapy then surgery
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II/III Randomized Multicentre Study Comparing Neoadjuvant Chemoradiotherapy Followed by Consolidation Chemotherapy to Neoadjuvant Chemoradiotherapy Alone in Non-metastatic Rectal Cancer Patients.
Actual Study Start Date : November 23, 2017
Estimated Primary Completion Date : May 30, 2021
Estimated Study Completion Date : November 23, 2025

Arm Intervention/treatment
Experimental: Experimental arm
Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and surgery. Consolidation chemotherapy will start 2-4 weeks after the end of CRT. Surgery will be performed 2-4 weeks after the last chemotherapy cycle. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (4 cycles of modified FOLFOX6 or 3 cycles of XELOX).
Drug: Chemotherapy
Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
Other Names:
  • Folfox
  • Xelox

No Intervention: Standard arm
Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).



Primary Outcome Measures :
  1. Pathologic complete response rate (pCR). [ Time Frame: 3 years ]
    pCR will be defined as the absence of viable tumor cells in the primary tumor and in the lymph nodes (ypT0N0) by histopathological assessment of the surgical specimen at the time of definitive rectal surgery.

  2. 3-year disease free survival (DFS) rate. [ Time Frame: 3 years ]
    3-year DFS will be defined as the percentage of patients alive without recurrence of disease at 3 years measured from the date of randomization


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 5 years ]
    defined as the time from randomization to death from any cause

  2. Radiological response by MRI imaging before surgery. [ Time Frame: 3 years ]
  3. Short and long-term toxicity. [ Time Frame: 3 - 5 years ]
    According to common toxicology criteria of adverse events, version 3

  4. Surgical complications. [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years at diagnosis
  • Histopathological diagnosis of rectal adenocarcinoma
  • ECOG Performance Status (PS): 0- 2
  • Clinical Stage: T2 N1-2, T3N0-2, T4 N0-2 based on pelvic MRI. Lymph node will be considered radiologically positive if: - size (short axis≥ 1cm) and/or - Morphological changes: irregular outlines/ abnormal signal intensity, positive enhancement.
  • The standard treatment recommendation of included patients in the absence of a clinical trial would be combined modality neoadjuvant CRT followed by curative intent surgical resection.
  • Primary surgeon is planning to perform Total Mesorectal Excision (TME).
  • The following laboratory values must be obtained ≤ 28 days prior to registration:

    • Absolute neutrophil count (ANC) ≥ 1500/mm3
    • Platelet count ≥ 100,000/mm3
    • Hemoglobin > 8.0 g/dl (transfusion permitted)
    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
    • SGOT (AST) ≤ 3 x ULN
    • SGPT (ALT) ≤ 3 x ULN
    • Creatinine ≤1.5 x ULN or Creatinine clearance > 50ml/minute by Cockcroft-Gault formula.
  • Negative pregnancy test ≤ 7 days prior to registration for women of childbearing potential only.
  • Patient of child-bearing potential is willing to employ an adequate contraception method
  • Provide informed written consent
  • Willing to return to the enrolling medical site for all study assessments

Exclusion Criteria:

  • Extensive growth into the sacrum or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is seen.
  • Presence of metastatic disease or recurrent rectal tumor.
  • Familial Adenomatosis Polyposis coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), active Crohn's disease or active ulcerative Colitis.
  • Concomitant malignancies, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must be disease-free for at least 5 years.
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency.
  • Any contraindications to MRI (e.g. patients with pacemakers)
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
  • Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac dysrhythmia, e.g. atrial fibrillation, even if controlled with medication) or myocardial infarction within the past 12 months.
  • Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract.
  • Co-morbid illnesses or other concurrent disease which, in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Any investigational treatment for rectal cancer within the past year.
  • Pregnancy or breast feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03957733


Contacts
Layout table for location contacts
Contact: Rania M Felemban, MSc +96625549999 ext 18013 felembanr@kamc.med.sa
Contact: Wedian O Almowlad, MSc +96625549999 ext 18004 Almwlld.W@kamc.med.sa

Locations
Layout table for location information
Saudi Arabia
King Abdullah Medical City, Holy Capital Recruiting
Mecca, Makkah Western, Saudi Arabia, 21955
Contact: Rania M Felemban, Msc    0096625549999 ext 18013    felembanr@kamc.med.sa   
Contact: Wedian O Almowlad, Msc    0096625549999 ext 18004    Almwlld.W@kamc.med.sa   
Sponsors and Collaborators
King Abdullah Medical City
King Faisal Specialist Hospital & Research Center
King Saud Medical City
Al Hada Military Hospital
Investigators
Layout table for investigator information
Principal Investigator: Shereef E Mohammad King Abdullah Medical City

Layout table for additonal information
Responsible Party: King Abdullah Medical City
ClinicalTrials.gov Identifier: NCT03957733     History of Changes
Other Study ID Numbers: 17-329
First Posted: May 21, 2019    Key Record Dates
Last Update Posted: May 21, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases